MAPK3 and Miyoshi myopathy: Reducing such systemic immune activation can be achieved by limiting transgenic boost in the spleens of mice with tamoxifen-inducible aid-cre-ERT2 or cγ1-cre-ERT2 alleles51,52; however, preliminary studies with the aid-cre-ERT2 model suggest that, while the splenic hyperplasia can be reduced, MM will be developed at late age and with a variable penetrance.